ES2980374T3 - Dinucleótidos cíclicos como agentes anticancerosos - Google Patents

Dinucleótidos cíclicos como agentes anticancerosos Download PDF

Info

Publication number
ES2980374T3
ES2980374T3 ES19712440T ES19712440T ES2980374T3 ES 2980374 T3 ES2980374 T3 ES 2980374T3 ES 19712440 T ES19712440 T ES 19712440T ES 19712440 T ES19712440 T ES 19712440T ES 2980374 T3 ES2980374 T3 ES 2980374T3
Authority
ES
Spain
Prior art keywords
pharmaceutically acceptable
compound
cancer
acceptable salt
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19712440T
Other languages
English (en)
Spanish (es)
Inventor
Brian E Fink
Zheming Ruan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES2980374T3 publication Critical patent/ES2980374T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES19712440T 2018-03-08 2019-03-07 Dinucleótidos cíclicos como agentes anticancerosos Active ES2980374T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862640325P 2018-03-08 2018-03-08
PCT/US2019/021145 WO2019173587A1 (en) 2018-03-08 2019-03-07 Cyclic dinucleotides as anticancer agents

Publications (1)

Publication Number Publication Date
ES2980374T3 true ES2980374T3 (es) 2024-10-01

Family

ID=65818709

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19712440T Active ES2980374T3 (es) 2018-03-08 2019-03-07 Dinucleótidos cíclicos como agentes anticancerosos

Country Status (7)

Country Link
US (1) US11945834B2 (https=)
EP (1) EP3762397B1 (https=)
JP (1) JP7250808B2 (https=)
KR (2) KR20200130362A (https=)
CN (1) CN111801341B (https=)
ES (1) ES2980374T3 (https=)
WO (1) WO2019173587A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11660311B2 (en) 2017-10-10 2023-05-30 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2021206158A1 (ja) 2020-04-10 2021-10-14 小野薬品工業株式会社 がん治療方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
AU2006230099B2 (en) 2005-03-25 2012-04-19 Gitr, Inc. GITR binding molecules and uses therefor
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
CA2634198C (en) 2005-12-20 2014-06-03 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
ES2444574T3 (es) 2006-09-19 2014-02-25 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de la indolamina 2,3-dioxigenasa
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
ES2776406T3 (es) 2007-07-12 2020-07-30 Gitr Inc Terapias de combinación que emplean moléculas de enlazamiento a GITR
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
JP5583592B2 (ja) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ｉｄｏ阻害剤
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP2473531A4 (en) 2009-09-03 2013-05-01 Merck Sharp & Dohme Anti-gitr antibodies
US8722720B2 (en) 2009-10-28 2014-05-13 Newlink Genetics Corporation Imidazole derivatives as IDO inhibitors
PH12012500881A1 (en) 2009-12-10 2017-07-26 Hoffmann La Roche Antibodies binding preferentially human csf1r extracellular domain 4 and their use
CA2789076C (en) 2010-03-05 2017-11-21 F. Hoffmann-La Roche Ag Antibodies against human colony stimulating factor-1 receptor and uses thereof
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
MX378336B (es) 2010-05-04 2025-03-10 Five Prime Therapeutics Inc Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r).
PT2614082T (pt) 2010-09-09 2018-12-03 Pfizer Moléculas de ligação a 4-1bb
NO2694640T3 (https=) 2011-04-15 2018-03-17
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
BR112014012624A2 (pt) 2011-12-15 2018-10-09 F Hoffmann-La Roche Ag anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
RU2014136332A (ru) 2012-02-06 2016-03-27 Дженентек, Инк. Композиции и способы применения ингибиторов csf1r
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
EP2847220A1 (en) 2012-05-11 2015-03-18 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
HK1204557A1 (en) 2012-05-31 2015-11-27 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-l1
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
JP6742903B2 (ja) 2013-05-02 2020-08-19 アナプティスバイオ インコーポレイティッド プログラム死−１（ｐｄ−１）に対する抗体
US9676853B2 (en) 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
MY184154A (en) 2013-12-12 2021-03-23 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
CR20180101A (es) * 2015-08-13 2018-04-12 Merck Sharp & Dohme Compuestos di-nucleóticos cíclicos como agonistas de sting
RS67188B1 (sr) * 2016-01-11 2025-10-31 Innate Tumor Immunity Inc Ciklični dinukleotidi za lečenje stanja povezanih sa aktivnošću sting kao što je kancer
WO2017123657A1 (en) * 2016-01-11 2017-07-20 Gary Glick Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
SG10201912074PA (en) * 2016-03-18 2020-02-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
WO2019043634A2 (en) * 2017-08-30 2019-03-07 Beijing Xuanyi Pharmasciences Co., Ltd. CYCLIC DI-NUCLEOTIDES AS STIMULATORS OF INTERFERON GENE MODULATORS
ES2904317T3 (es) * 2017-08-31 2022-04-04 Bristol Myers Squibb Co Dinucleótidos cíclicos como agentes anticancerosos
US10947263B2 (en) * 2017-08-31 2021-03-16 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
US11667663B2 (en) * 2017-08-31 2023-06-06 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
US11660311B2 (en) * 2017-10-10 2023-05-30 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
US11427610B2 (en) * 2017-10-16 2022-08-30 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents

Also Published As

Publication number Publication date
KR20200130362A (ko) 2020-11-18
US11945834B2 (en) 2024-04-02
US20210002323A1 (en) 2021-01-07
JP2021515016A (ja) 2021-06-17
CN111801341B (zh) 2023-10-24
CN111801341A (zh) 2020-10-20
EP3762397B1 (en) 2024-05-01
WO2019173587A1 (en) 2019-09-12
EP3762397A1 (en) 2021-01-13
KR20250125433A (ko) 2025-08-21
JP7250808B2 (ja) 2023-04-03

Similar Documents

Publication Publication Date Title
ES2904317T3 (es) Dinucleótidos cíclicos como agentes anticancerosos
ES2945140T3 (es) Dinucleótidos cíclicos como agentes anticancerosos
ES2997757T3 (en) Cyclic dinucleotides as anticancer agents
US11667663B2 (en) Cyclic dinucleotides as anticancer agents
ES2932354T3 (es) Dinucleótidos cíclicos como agentes anticáncer
ES3058522T3 (en) Cyclic dinucleotides as anticancer agents
ES2909616T3 (es) Dinucleótidos cíclicos como agentes anticáncer
ES2980374T3 (es) Dinucleótidos cíclicos como agentes anticancerosos